作者: Peter Lembke
DOI: 10.1007/978-1-62703-215-5_19
关键词:
摘要: During the last 20 years there has been a clear shift from standard “18/12” fish oils—where “18” stands for 18% eicosapentaenoic acid (EPA) and “12” 12% docosahexaenoic (DHA)—to concentrated “omega-3 oils.” It was gradual process over most of years, but lately demand high omega-3 oils increased dramatically. A first step achieved by eliminating saturated mono-unsaturated fatty acids in this way reaching EPA + DHA concentrations 50–55%. This concentrate became very popular past couple is often referred to as “33/22.” Then, due commercial success Lovaza (Omacor), concentrates 85% significantly trend highly (EPA 96%) observed, likely based on soon-to-be-commercialized Amarin drug AMR101. Today are only handful companies worldwide that able produce and/or products with more than 95% purity, will change near future owing growing such products.